(1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one

• ChemBase编号: 1062
• 分子式: C17H19NO4
• 平均质量: 301.33706
• 单一同位素质量: 301.13140809
• SMILES: O1[C@@H]2[C@]34[C@](O)([C@H](N(CC3)C)Cc3c4c1c(O)cc3)CCC2=O
• Canonical SMILES: O=C1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)C)ccc1O)O
• InChI: InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1
• InChIKey: UQCNKQCJZOAFTQ-ISWURRPUSA-N

名称和登记号

名称

• IUPAC标准名: (1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one
• IUPAC传统名: oxymorphone
• 商标名: Numorphan; Opana; OPANA ER
• 别名: Dihydrohydroxymorphinone; Dihydroxymorphinone; Oxymorphine; 14-Hydroxydihydromorphinone; Oximorphonum; oxymorphone; EN3202; Oxymorphone

登记号

• CAS号: 76-41-5
• PubChem SID: 160964525; 46505296
• PubChem CID: 5284604

理论计算性质

JChem

• Acid pKa: 10.07158
• 质子受体: 5
• 质子供体: 2
• LogD (pH = 5.5): -1.7639712
• LogD (pH = 7.4): 0.008845229
• Log P: 0.78487325
• 摩尔折射率: 79.5595 cm^3
• 极化性: 31.115646 Å^3
• 极化表面积: 70.0 Å^2
• 可自由旋转的化学键: 0
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.26
• LOG S: -1.07
• 溶解度: 2.56e+01 g/l

分子性质

理化性质

• 溶解度: 2.4E+004 mg/L
• 疏水性(logP): 0

详细说明

DrugBank - DB01192

• Drug Groups: approved; investigational
• Description: An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)
• Indication: For the treatment of moderate-to-severe pain.
• Pharmacology: Oxymorphone is a semi-synthetic opioid substitute for morphine. It is a potent analgesic. Opioid analgesics exert their principal pharmacologic effects on the CNS and the gastrointestinal tract. The principal actions of therapeutic value are analgesia and sedation. Opioids produce respiratory depression by direct action on brain stem respiratory centers. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.
• Toxicity: Oxymorphone overdosage is characterized by respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In a severe case of overdose, apnea, circulatory collapse, cardiac arrest, and death may occur. Intravenous mouse LD₅₀ is 172 mg/kg.
• Affected Organisms: Humans and other mammals
• Biotransformation: Oxymorphone undergoes extensive hepatic metabolism in humans. After a 10 mg oral dose, 49% was excreted over a five-day period in the urine. Of this, 82% was excreted in the first 24 hours after administration. The recovered drug-related products contained the oxymorphone (1.9%), the conjugate of oxymorphone (44.1%), the 6(beta)-carbinol produced by 6-keto reduction of oxymorphone (0.3%), and the conjugates of 6(beta)-carbinol (2.6%) and 6(alpha)-carbinol (0.1%).
• Half Life: 1.3 (+/-0.7) hours
• Elimination: Oxymorphone is highly metabolized, principally in the liver, and undergoes reduction or conjugation with glucuronic acid to form both active and inactive products. Because oxymorphone is extensively metabolized, <1% of the administered dose is excreted unchanged in the urine.
• External Links: Wikipedia; RxList; Drugs.com